154 related articles for article (PubMed ID: 33390785)
41. The diagnostic and prognostic value of H2AFY in hepatocellular carcinoma.
Ma X; Ding Y; Zeng L
BMC Cancer; 2021 Apr; 21(1):418. PubMed ID: 33858382
[TBL] [Abstract][Full Text] [Related]
42. H2.0-like homeobox 1 acts as a tumor suppressor in hepatocellular carcinoma.
Liu T; Chen J; Xiao S; Lei X
Tumour Biol; 2016 May; 37(5):6419-28. PubMed ID: 26631039
[TBL] [Abstract][Full Text] [Related]
43. Long non-coding RNA CARLo-5 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients.
Wang F; Xie C; Zhao W; Deng Z; Yang H; Fang Q
Clin Exp Med; 2017 Feb; 17(1):33-43. PubMed ID: 26433964
[TBL] [Abstract][Full Text] [Related]
44. Clinicopathological and Prognostic Value of Plasma CD24 Level in Hepatocellular Carcinoma.
Maimaitiming A; Zhou X; Ma X; Huang Y; Wang Q; Deng R; Ren Y; Chai X; Zhang P
J Invest Surg; 2020 Jul; 33(6):536-541. PubMed ID: 30543135
[No Abstract] [Full Text] [Related]
45. Expression of FOXJ1 in hepatocellular carcinoma: correlation with patients' prognosis and tumor cell proliferation.
Chen HW; Huang XD; Li HC; He S; Ni RZ; Chen CH; Peng C; Wu G; Wang GH; Wang YY; Zhao YH; Zhang YX; Shen AG; Wang HM
Mol Carcinog; 2013 Aug; 52(8):647-59. PubMed ID: 22488567
[TBL] [Abstract][Full Text] [Related]
46. NEK2 serves as a prognostic biomarker for hepatocellular carcinoma.
Li G; Zhong Y; Shen Q; Zhou Y; Deng X; Li C; Chen J; Zhou Y; He M
Int J Oncol; 2017 Feb; 50(2):405-413. PubMed ID: 28101574
[TBL] [Abstract][Full Text] [Related]
47. High VRK1 expression contributes to cell proliferation and survival in hepatocellular carcinoma.
Huang W; Cui X; Chen Y; Shao M; Shao X; Shen Y; Liu Q; Wu M; Liu J; Ni W; Lu C; Wan C
Pathol Res Pract; 2016 Mar; 212(3):171-8. PubMed ID: 26706601
[TBL] [Abstract][Full Text] [Related]
48. Serine/arginine rich splicing factor 2 expression and clinic pathological features indicating a prognostic factor in human hepatocellular carcinoma patients.
Wang P; Guo L; Li K; Ning S; Shi W; Liu Z; Chen Y
Cancer Biomark; 2018 Feb; 21(3):681-687. PubMed ID: 29278882
[TBL] [Abstract][Full Text] [Related]
49. Expression of NEDD9 in hepatocellular carcinoma and its clinical significance.
Lu P; Wang ZP; Dang Z; Zheng ZG; Li X; Zhou L; Ding R; Yue SQ; Dou KF
Oncol Rep; 2015 May; 33(5):2375-83. PubMed ID: 25812772
[TBL] [Abstract][Full Text] [Related]
50. Serum long noncoding RNA urothelial carcinoma-associated 1: A novel biomarker for diagnosis and prognosis of hepatocellular carcinoma.
Zheng ZK; Pang C; Yang Y; Duan Q; Zhang J; Liu WC
J Int Med Res; 2018 Jan; 46(1):348-356. PubMed ID: 28856933
[TBL] [Abstract][Full Text] [Related]
51. Increased expression of cathepsin L: a novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients.
Ruan J; Zheng H; Fu W; Zhao P; Su N; Luo R
PLoS One; 2014; 9(11):e112136. PubMed ID: 25384089
[TBL] [Abstract][Full Text] [Related]
52. Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma.
Hong B; Qian Y; Zhang H; Sang YW; Cheng LF; Wang Q; Gao S; Zheng M; Yao HP
World J Gastroenterol; 2016 May; 22(18):4538-46. PubMed ID: 27182163
[TBL] [Abstract][Full Text] [Related]
53. Tissue microarray-based study of hepatocellular carcinoma validating SPIB as potential clinical prognostic marker.
Ho YJ; Lin YM; Huang YC; Yeh KT; Lin LI; Lu JW
Acta Histochem; 2016 Jan; 118(1):38-45. PubMed ID: 26610895
[TBL] [Abstract][Full Text] [Related]
54. CISD2 associated with proliferation indicates negative prognosis in patients with hepatocellular carcinoma.
Chen B; Shen S; Wu J; Hua Y; Kuang M; Li S; Peng B
Int J Clin Exp Pathol; 2015; 8(10):13725-38. PubMed ID: 26722601
[TBL] [Abstract][Full Text] [Related]
55. Canopy Homolog 2 Expression Predicts Poor Prognosis in Hepatocellular Carcinoma with Tumor Hemorrhage.
Wang D; Wang ZM; Zhang S; Wu HJ; Tao YM
Cell Physiol Biochem; 2018; 50(6):2017-2028. PubMed ID: 30415246
[TBL] [Abstract][Full Text] [Related]
56. [Up-regulator of cell proliferation predicts poor prognosis in hepatocellular carcinoma].
Xie C; Li J; Xie DY; Lin BL; Li MF; Gao ZL
Zhonghua Yi Xue Za Zhi; 2013 Jul; 93(27):2167-73. PubMed ID: 24284254
[TBL] [Abstract][Full Text] [Related]
57. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
58. TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis.
Wang Y; He D; Yang L; Wen B; Dai J; Zhang Q; Kang J; He W; Ding Q; He D
Biochem Biophys Res Commun; 2015 Jul; 463(3):458-65. PubMed ID: 26043685
[TBL] [Abstract][Full Text] [Related]
59. Decreased expression of LncRNA SRA1 in hepatocellular carcinoma and its clinical significance.
Luo P; Jing W; Zhu M; Li ND; Zhou H; Yu MX; Liang CZ; Tu JC
Cancer Biomark; 2017; 18(3):285-290. PubMed ID: 28085012
[TBL] [Abstract][Full Text] [Related]
60. Prognostic Significance of 14-3-3ε, Aldo-keto Reductase Family 1 B10 and Metallothionein-1 in Hepatocellular Carcinoma.
Wu CY; Jan YJ; Ko BS; Wu YJ; Wu YJ; Liou JY
Anticancer Res; 2018 Dec; 38(12):6855-6863. PubMed ID: 30504401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
